Library — CHDR

Search

Filter

Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.

Leebeek FW, Kluft C, Knot EA, Los P, Cohen AF, Six AJ

Journal of the American College of Cardiology, 1990 May; 15(6):1212-20

View publication
Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers.

de Boer A, Danhof M, Cohen AF, Magnani HN, Breimer DD

Thrombosis and haemostasis, 1991 Jul; 66(2):202-7

View publication
Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects.

de Boer A, Kluft C, Gerloff J, Dooijewaard G, Günzler WA, Beier H, van der Meer FJ, Cohen AF

Thrombosis and haemostasis, 1993 Aug; 70(2):320-5

View publication
Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction.

van Griensven JM, Koster RW, Hopkins GR, Beier H, Günzler WA, Kroon R, Schoemaker RC, Cohen AF

Thrombosis and haemostasis, 1997 Aug; 78(3):1015-20

View publication
Pharmacodynamics and pharmacokinetics of the novel thrombopoietin mimetic peptide RWJ-800088 in humans.

Liem-Moolenaar M, Cerneus D, Molloy CJ, End D, Brown KH, de Kam ML, Cohen AF, van Hensbergen Y, Burggraaf J

Clinical pharmacology and therapeutics, 2008 Sep; 84(4):481-7

View publication
Introduction to haemostasis from a pharmacodynamic perspective.

Kluft C, Burggraaf J

British journal of clinical pharmacology, 2011 Sep; 72(4):538-46

View publication
Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.

Ducore J, Lawrence JB, Simpson M, Boggio L, Bellon A, Burggraaf J, Stevens J, Moerland M, Frieling J, Reijers J, Wang M

Haemophilia : the official journal of the World Federation of Hemophilia, 2018 Feb; 23(6):844-851

View publication
Sex hormone-binding globulin as a marker for the thrombotic risk of hormonal contraceptives: a rebuttal.

Kluft C, Skouby SO, Jespersen J, Burggraaf J

Journal of thrombosis and haemostasis : JTH, 2013 Jan; 11(2):394-5

View publication
Effects of sugammadex on activated partial thromboplastin time and prothrombin time in healthy subjects.

De Kam PJ, Grobara P, Prohn M, Höppener F, Kluft C, Burggraaf J, Langdon RB, Peeters P

International journal of clinical pharmacology and therapeutics, 2014 Feb; 52(3):227-36

View publication

«
1
2
3
4
5
6
»